Brief: Pila Pharma Achieves Preclinical Proof-Of-Concept In Cardiovascular Study
18/12/2024 14:02
Dec 18 (Reuters) - Pila Pharma AB PILA.ST :
* ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN
CARDIOVASCULAR DISEASE STUDY
* TRPV1 ANTAGONIST, XEN-D0501, SIGNIFICANTLY REDUCED
ABDOMINAL
AORTA ANEURYSM GROWTH IN MICE
Source text: ID:nBQN5w8fqv
Further company coverage: PILA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))